Navigation Links
Osseon Signs International Distribution Agreement With MBA Incorporado
Date:9/22/2009

SANTA ROSA, Calif., Sept. 22 /PRNewswire/ -- Osseon Therapeutics, Inc., a Santa Rosa, California, manufacturer of spinal medical devices for the minimally invasive treatment of spinal compression fractures, today announced it has signed a five-year agreement with MBA Incorporado, SL to distribute Osseon's suite of products in the European and South American markets. MBA is a leading medical device marketing and distribution organization and specializes in the sale of products used for treatment of the spine. MBA is the largest private independent distributor of orthopaedic devices in Europe, generating more than $100 million in total sales in 2008.

Osseon's product line features the Osseoflex and Osseoperm. These products combine to form a unique new procedure termed Osseoplasty to treat painful acute fractures of the vertebrae seen increasingly in older individuals with osteoporosis and osteo-traumatic injuries.

Osseoflex is a steerable and curvable needle that can access the majority of the vertebral body from a single percutaneous access point. The Osseoperm system is customized for delivering optimal viscosity cement and precise cement placement through the Osseoflex needle. The Osseoplasty procedure provides rapid stabilization of vertebral fractures and significant pain relief in most patients within the same day.

MBA will distribute Osseon's devices to physicians and hospitals throughout the European Union, including the United Kingdom, Germany, Spain, Portugal, Italy, Greece, Austria, Switzerland, Scandinavia, France, Benelux, Turkey and Germany, as well as Latin America.

"Osseon is excited to partner with MBA, the leading distributor of biomedical spine treatment products in Europe and South America," said Dr. John Stalcup, CEO of Osseon Therapeutics. "MBA is known as the 'state-of-the-science' innovator in these markets for medical devices, always at the forefront of distribution and support of advanced medical technologies. Having MBA as our exclusive distributor will bring immediate and long-lasting relationships with the leading physicians and hospitals treating spinal compression fractures. We are, indeed, pleased to have MBA as our sole representative."

Paul Griffin, MBA's Chief Operating Officer and a member of their Board of Directors said, "MBA is honored that Osseon has chosen our Organization as its marketing and distribution partner for this unique technology for Europe and South America. We are delighted with this Agreement, which represents a huge opportunity for both our Organizations to facilitate the introduction of this exciting and new therapeutic option to specialists in many countries outside the U.S., who are treating an ever-increasing number of painful vertebral compression fractures in older patients." Paul Griffin added, "We feel confident that the combination of Osseon's impressive product portfolio together with MBA's experienced team and marketing know-how will allow us to develop and grow a very successful business together as innovators in this key market. Osseon has state-of-the-art technology and MBA has the resources to bring these remarkable devices quickly and successfully into all of the major and most competitive markets outside the U.S."

"MBA has an excellent and long-established international reputation for marketing and distributing medical devices for independent innovators and an unparalleled reputation for customer service. The Agreement today between MBA and Osseon represents a major step forward in the expansion of these services into the key markets of Europe and Latin America."

Osseon Therapeutics, Inc. was incubated at the University of Northern California's Science and Technology Innovation Center in Santa Rosa. Its first-generation products have received both FDA clearance and CE Mark for product distribution in the United States and European Union.

To learn more about Osseon, please visit our website:http://www.osseon.com/


'/>"/>
SOURCE Osseon Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Osseon Receives CE Mark
2. New device finds early signs of eye disease in preemies
3. GENova Biotherapeutics signs LOI with Korean university for stem cell research and patents sharing
4. GENova Biotherapeutics signs engagement agreement with PacificWave Partners Limited
5. Haemonetics Signs Comprehensive Agreement with Blood Centers of America
6. GENova Biotherapeutics signs collaboration agreement with Prime BioResearch
7. GENova Biotherapeutics and Prime BioResearch signs LOI on diabetes and cancer cure
8. HemCon Medical Technologies, Inc. signs exclusive global agreement with Zimmer Dental Inc. to distribute oral surgery dressings
9. Access Pharmaceuticals Signs Agreement to Manufacture Its FDA-Approved MuGard in the United States
10. Online Sign Making from Genuinesigns.com Just Got Faster, Easier, & Greener with its New Revolutionary System
11. Patient Safety Technologies Signs Contract with Partners HealthCare, to Implement the Safety-Sponge(TM) System at Brigham & Womens Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , ... March 28, 2017 , ... ... is the first technology to directly address the resolution to globally reduce the ... is a patented compound of FDA and TTB approved ingredients that when infused ...
(Date:3/28/2017)... ... 29, 2017 , ... The Thyroid Secret is a specialized ... The program was recently launched on March 1, and Dr. Wentz discussed varied ... , Dr. Izabella Wentz is a licensed pharmacist and a foremost thyroid specialist. ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... dedicated to advancing the science and clinical practice of radiosurgery, announced today ... Registry, a multi-institutional, observational registry established to standardize data collection from patients ...
(Date:3/28/2017)... DC (PRWEB) , ... March 28, 2017 , ... WHO: ... Dr. Toni Bark , WHAT: , Medical doctors and PhD scientists will speak to ... written to President Trump in support of an independent vaccine safety commission. , ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... Paul Yost, will begin serving as new board chair for Orange County health ... will serve the remainder of soon-to-be former chair Mark Refowitz’s term, which runs ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017  Rosen Law Firm, a ... a class action lawsuit on behalf of purchasers of ... ) pursuant and/or traceable to Kitov,s initial public offering ... on the open market from November 20, 2015 through ... The lawsuit seeks to recover damages for Kitov investors ...
(Date:3/28/2017)... , March 29, 2017 ... Siteless CRO platform, announced today study results ... Managed Care Pharmacy, #AMCP2017, Managed Care and Specialty Pharmacy ... . Data in both posters demonstrated that pharmacist-led ... and protocol adherence. These factors are crucial to generating ...
(Date:3/28/2017)... , March 28, 2017 Emosis SAS, ... new business entity, Emosis Ltd, headquartered in Tel Aviv ... novel assays complementing the mother company existing technology platform and test ... sales development of Emosis kits. ... This strategic move starts building Emosis international footprint. Emosis ...
Breaking Medicine Technology: